Source: Cure Today articles
Triplet therapy demonstrates improved remission and survival rates, with manageable side effects for patients who are ineligible for transplant.
Recent Content
- The influencing factors of renal response in newly diagnosed multiple myeloma patients with renal impairment
- Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma
- Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma
- CT-defined body composition as a prognostic factor in multiple myeloma
- MRD Testing Made a Myeloma Survivor Feel ‘OK to Be Safe’
- CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability
- Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
- Different Translocations of Multiple Myeloma on Fluorescent <em>In Situ</em> Hybridization (FISH) with Clinical Correlation
- Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
- Isatuximab in multiple myeloma